October 10, 2025 - 03:01

Lisata Therapeutics, Inc. has announced the initiation of a global product license agreement with Catalent, Inc. This collaboration allows Catalent to integrate Lisata’s innovative certepetide into antibody-drug conjugates (ADCs) utilizing Catalent’s advanced SMARTag technology platform. This partnership highlights the adaptability of certepetide and strategically positions Lisata’s technology within a prominent ADC framework.
The agreement is expected to enhance the development of novel therapeutics, combining Lisata's unique peptide with Catalent's cutting-edge technology. By leveraging each other's strengths, both companies aim to accelerate the creation of targeted cancer therapies that could significantly improve patient outcomes.
Lisata’s commitment to advancing its therapeutic offerings is underscored by this collaboration, which not only validates the potential of certepetide but also underscores the growing importance of ADCs in oncology. As both companies move forward, the partnership is anticipated to pave the way for innovative treatments in the fight against cancer.
November 21, 2026 - 21:58
Suspected Breach Hits FBI National Crime DatabaseThe reported hacking is the latest in a string of breaches and outages affecting the US government. Recent investigations suggest that the FBI`s national crime database may have been compromised,...
November 21, 2026 - 10:40
Norway's Shift from Digital Screens to Smart Glasses in EducationThree years ago, a schoolteacher in Norway faced criticism for prioritizing traditional pen and paper over iPads in his classroom. This incident highlights a significant shift in educational...
November 20, 2026 - 23:55
Corning Stock Plummets Amid Technology Market DeclineCorning shares experienced a significant drop of 10.6%, closing at $94.70 as the technology sector faced a widespread sell-off. The decline in Corning`s stock mirrored broader trends in the market,...
November 20, 2026 - 04:38
Shield Achieves Third Consecutive Year on Deloitte Technology Fast 500This marks Shield`s third consecutive year of recognition in both reports since the category was established. The company continues to stand out in the competitive landscape of technology firms,...